Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation

Nutrition

Volumn 30, Issue 7-8, 2014, Pages 915-919

  Andrade, João Marcus Oliveira ^a   Paraíso, Alanna Fernandes ^a   de Oliveira, Marcos Vinícius Macedo ^a,d   Martins, Andréa Maria Eleutério ^a   Neto, João Felício ^a   Guimarães, André Luiz Sena ^a   de Paula, Alfredo Maurício ^a   Qureshi, Mahboob ^c   Santos, Sérgio Henrique Sousa ^a,b  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c TOURO UNIVERSITY NEVADA   (United States)

^d Faculdades Integradas Pitagoras   (Brazil)

Author keywords

Inflammation; Nonalcoholic fatty liver disease; Obesity; Resveratrol; SIRT1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; AMINOTRANSFERASE; CYTOKINE; LIPID; PLANT EXTRACT; STILBENE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; FOOD COMPOSITION; FOOD INTAKE; GENE EXPRESSION REGULATION; INFLAMMATION; LIPID DIET; LIPID METABOLISM; LIPOGENESIS; LIVER HISTOLOGY; LIVER PROTECTION; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; INBRED MOUSE STRAIN; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYTOTHERAPY;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; CYTOKINES; DIET, HIGH-FAT; INFLAMMATION; INSULIN; LIPIDS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED STRAINS; NF-KAPPA B; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHYTOTHERAPY; PLANT EXTRACTS; RNA, MESSENGER; STILBENES; TRANSAMINASES;

EID: 84903384321     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.11.016     Document Type: Article

References (38)

1. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
2. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
3. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 2010, 5:145-171.
4. Mendez-Sanchez N., Arrese M., Zamora-Valdes D., Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007, 27:423-433.
5. Qureshi K., Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007, 13:3540-3553.
6. Sanyal A.J. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
7. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
8. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
9. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the invivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
10. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 2000, 47:549-555.
11. Das S., Das D.K. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007, 2:133-138.
12. de la Lastra C.A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007, 35:1156-1160.
13. Delmas D., Lancon A., Colin D., Jannin B., Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006, 7:423-442.
14. Das S., Das D.K. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007, 6:168-173.
15. Beaudeux J.L., Nivet-Antoine V., Giral P. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome?. Curr Opin Clin Nutr Metab Care 2010, 13:729-736.
16. Carafa V., Nebbioso A., Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol 2012, 3:4.
17. Lavu S., Boss O., Elliott P.J., Lambert P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008, 7:841-853.
18. Colak Y., Ozturk O., Senates E., Tuncer I., Yorulmaz E., Adali G., et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monitor Int Med J Exp Clin Res 2011, 17:HY5-HY9.
19. Deng X.Q., Chen L.L., Li N.X. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007, 27:708-715.
20. Alberdi G., Rodriguez V.M., Miranda J., Macarulla M.T., Churruca I., Portillo M.P. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. Food Chem 2013, 141:1530-1535.
21. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006, 127:1109-1122.
22. Feltenberger J.D., Andrade J.M., Paraiso A., Barros L.O., Filho A.B., Sinisterra R.D., et al. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013, 62:324-330.
23. Santos S.H., Fernandes L.R., Mario E.G., Ferreira A.V., Porto L.C., Alvarez-Leite J.I., et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008, 57:340-347.
24. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., Garcia-Urkia N., et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008, 8:40.
25. Wang G.L., Fu Y.C., Xu W.C., Feng Y.Q., Fang S.R., Zhou X.H. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophysical Res Comm 2009, 380:644-649.
26. Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., et al. SIRT1 deacetylates and inhibits SREBP-1 C activity in regulation of hepatic lipid metabolism. J Biol Chem 2010, 285:33959-33970.
27. Moran-Salvador E., Lopez-Parra M., Garcia-Alonso V., Titos E., Martinez-Clemente M., Gonzalez-Periz A., et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 2011, 25:2538-2550.
28. Pettinelli P., Videla L.A. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1 c induction. J Clin Endocrinol Metab 2011, 96:1424-1430.
29. Olholm J., Paulsen S.K., Cullberg K.B., Richelsen B., Pedersen S.B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010, 34:1546-1553.
30. Santos S.H., Fernandes L.R., Pereira C.S., Guimaraes A.L., de Paula A.M., Campagnole-Santos M.J., et al. Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Reg Peptides 2012, 178:64-70.
31. Santos S.H., Andrade J.M., Fernandes L.R., Sinisterra R.D., Sousa F.B., Feltenberger J.D., et al. Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-kappaB in rats fed with high-fat diet. Peptides 2013, 46:47-52.
32. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788.
33. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liverdisease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
34. Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metabol 2009, 9:327-338.
35. Yoshizaki T., Milne J.C., Imamura T., Schenk S., Sonoda N., Babendure J.L., et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009, 29:1363-1374.
36. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008, 105:9793-9798.
37. Rahman I., Marwick J., Kirkham P. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol 2004, 68:1255-1267.
38. Salminen A., Kauppinen A., Suuronen T., Kaarniranta K. SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: regulation of aging via NF-kappaB acetylation?. BioEssays 2008, 30:939-942.